Guy Reed, MD, began more than a decade ago to research a safer, more effective therapy for dissolving blood clots, which are the cause of most strokes. The outcome of that research is a novel thrombus (blood clot) dissolving agent, TS23, which is currently undergoing clinical trials.
UTHSC
UTRF Health Science Center Office Seeking Commercialization Analyst Intern
Click to apply for UTRF internship.
UTHSC 2016 Office Intern Q&A
Where are you from originally? Helene: I am originally from France. Why did you choose UT? Helene: I had the opportunity to do a postdoc at UT, which I started in July 2015. I have a PhD in microbiology. Why did you choose to intern with UTRF? Helene: Out of curiosity and interest! I saw this (read more)